EMITT-1: Clinical activity of oral ERAP1 inhibitor GRWD5769 and cemiplimab in phase 1b expansion cohorts in solid tumors with anti–PD-1 resistance: A novel approach to diversify tumor immunogenicity
Open Internet by MindsNet
EMITT-1: Clinical activity of oral ERAP1 inhibitor GRWD5769 and cemiplimab in phase 1b expansion cohorts in solid tumors with anti–PD-1 resistance: A novel approach to diversify tumor immunogenicity